Meeting
2016 ASCO Annual Meeting
Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16).
Authors
Kosuke Kawaguchi
Graduate School of Medicine Kyoto University, Kyoto, Japan
Kosuke Kawaguchi , Eiji Suzuki , Tatsuki R Kataoka , Masahiro Hirata , Shinji Ohno , Hiroko Bando , Hiroshi Ishiguro , Kenichi Inoue , Naohito Yamamoto , Katsumasa Kuroi , Satoshi Morita , Norikazu Masuda , Masakazu Toi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
000007576
Citation
J Clin Oncol 34, 2016 (suppl; abstr 599)
DOI
10.1200/JCO.2016.34.15_suppl.599
Abstract #
599
Poster Bd #
87
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.
First Author: Christian F. Singer
Poster
2021 ASCO Annual Meeting
ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.
First Author: Giampaolo Bianchini
Poster
2019 ASCO Annual Meeting
NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response (pCR).
First Author: Sandra M. Swain
Poster
2019 ASCO Annual Meeting
Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.
First Author: Ning Liao